Clearance of chronic hepatitis B virus infection in young children after alpha interferon treatment

J Pediatr. 1995 Nov;127(5):815-8. doi: 10.1016/s0022-3476(95)70181-8.

Abstract

Nine children aged 18 months to 17 years (mean 5.7 years) with chronic hepatitis b virus infection and chronic active hepatitis were treated with 5 to 6 million units/m2 of body surface area of interferon -alpha 2b administered subcutaneously three times per week for 4 months (n = 1) or 6 months (n = 8). At 12 months after the start of therapy, six children less than 3 years of age responded to the treatment (three completely and three partially), whereas only one of three children older than 7 years of age responded. We conclude that IFN treatment may be effective in children with chronic HBV infection, especially when administered while they are young.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Analysis of Variance
  • Child
  • Child, Preschool
  • Female
  • Hepatitis B / blood
  • Hepatitis B / therapy*
  • Hepatitis, Chronic / blood
  • Hepatitis, Chronic / therapy*
  • Humans
  • Infant
  • Interferon alpha-2
  • Interferon-alpha / adverse effects
  • Interferon-alpha / therapeutic use*
  • Male
  • Pilot Projects
  • Recombinant Proteins
  • Remission Induction
  • Statistics, Nonparametric
  • Time Factors

Substances

  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins